Details

Autor(en) / Beteiligte

• Larkin, James
• Ascierto, Paolo A
• Dréno, Brigitte
• Atkinson, Victoria
• Liszkay, Gabriella
• Maio, Michele
• Mandalà, Mario
• Demidov, Lev
• Stroyakovskiy, Daniil
• Thomas, Luc
• de la Cruz-Merino, Luis
• Dutriaux, Caroline
• Garbe, Claus
• Sovak, Mika A
• Chang, Ilsung
• Choong, Nicholas
• Hack, Stephen P
• McArthur, Grant A
• Ribas, Antoni

Titel

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Ist Teil von

• The New England journal of medicine, 2014-11, Vol.371 (20), p.1867-1876

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• The combination of inhibitors to BRAF and MEK improved response rates and progression-free survival among patients with metastatic melanoma. Some toxicity was increased, but the incidence of second skin cancers was drastically reduced by the combination therapy. Approximately 50% of metastatic cutaneous melanomas harbor a BRAF V600 mutation, resulting in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. 1 , 2 These discoveries led to the development of agents that specifically target this driver mutation. The BRAF inhibitor vemurafenib (Zelboraf, Genentech) was approved worldwide on the basis of results from a phase 3 trial showing improved progression-free survival and overall survival, as compared with chemotherapy alone; the relative reduction in the risk of death was 63% and in the risk of disease progression was 74%. 3 Similar results were also reported for another BRAF inhibitor, dabrafenib, 4 which has also . . .